0001209191-23-041355.txt : 20230705
0001209191-23-041355.hdr.sgml : 20230705
20230705202041
ACCESSION NUMBER: 0001209191-23-041355
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230703
FILED AS OF DATE: 20230705
DATE AS OF CHANGE: 20230705
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nuss John
CENTRAL INDEX KEY: 0001874108
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40928
FILM NUMBER: 231071683
MAIL ADDRESS:
STREET 1: C/O VENTYX BIOSCIENCES, INC.
STREET 2: 332 ENCINITAS BLVD. SUITE 200
CITY: ENCINITAS
STATE: CA
ZIP: 92024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ventyx Biosciences, Inc.
CENTRAL INDEX KEY: 0001851194
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832996852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 662 ENCINITAS BLVD., STE. 250
CITY: ENCINITAS
STATE: CA
ZIP: 92024
BUSINESS PHONE: (858) 945-2393
MAIL ADDRESS:
STREET 1: 662 ENCINITAS BLVD., STE. 250
CITY: ENCINITAS
STATE: CA
ZIP: 92024
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-07-03
0
0001851194
Ventyx Biosciences, Inc.
VTYX
0001874108
Nuss John
C/O VENTYX BIOSCIENCES, INC.
ENCINITAS BLVD, SUITE 250
ENCINITAS
CA
92024
0
1
0
0
Chief Scientific Officer
0
Common Stock
2023-07-03
4
M
0
20000
0.20
A
264815
D
Common Stock
2023-07-03
4
S
0
327
33.5442
D
264488
D
Common Stock
2023-07-03
4
S
0
142
34.7231
D
264346
D
Common Stock
2023-07-03
4
S
0
20
35.2737
D
264326
D
Common Stock
2023-07-03
4
S
0
2266
38.3193
D
262060
D
Common Stock
2023-07-03
4
S
0
1563
39.3348
D
260497
D
Common Stock
2023-07-03
4
S
0
15682
39.9643
D
244815
D
Stock Option (right to buy)
0.20
2023-07-03
4
M
0
20000
0.00
D
2030-05-01
Common Stock
20000
26778
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022.
Represents the weighted average share price of an aggregate total of 327 shares sold in the price range of $33.28 to $34.1123. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 142 shares sold in the price range of $34.2706 to $35.2163. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 2,266 shares sold in the price range of $37.9611 to $38.9601. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 1,563 shares sold in the price range of $38.9668 to $39.6514. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 15,682 shares sold in the price range of $39.70 to $40.0506. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 1, 2020.
/s/ Christopher Krueger, as Attorney-in-Fact
2023-07-05